Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-12-14
Based on 122 first isolates · ICU · Skin / wound infection · 2024-12-15 → 2025-12-14
Intensive care unit
Per-organism detail: ICU wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 56 % (47 %–64 %)
Best two-drug combination: vancomycin + meropenem covers 98 % (94 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (15 %), Escherichia coli (14 %), Citrobacter freundii (7 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
56 %
57 %
n = 7
meropenem MEM
trend · Pseudomonas aeruginosa reserve
43 %
43 %
n = 7
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
43 %
57 %
n = 7
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
40 %
43 %
n = 7
37 %
43 %
n = 7
ceftriaxone CRO
trend · Escherichia coli
30 %
29 %
n = 7
25 %
29 %
n = 7
23 %
0 %
n = 7
12 %
14 %
n = 7
mecillinam MEC
not for this site
0 %
0 %
n = 7
trimethoprim TMP
not for this site
0 %
0 %
n = 7
nitrofurantoin NIT
not for this site
0 %
0 %
n = 7

Most likely organisms for this profile

Staphylococcus aureus
45 %
Pseudomonas aeruginosa
15 %
Escherichia coli
14 %
Enterococcus faecalis
11 %
Citrobacter freundii
7 %
Proteus mirabilis
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.